Phase Holographic Imaging (PHI) has two option programs, both with a final subscription date of October 24, 2017. The programs, directed to board members and advisors of the Company, were implemented as the Company was listed at AktieTorget. The options are market valued according to Black & Scholes. After recalculation with reference to equity issues, option program 2012 qualified for subscription of 43 872 shares at 16.50 SEK per share (originally 40 000 shares at 18.12 SEK) per share and option program 2013 for subscription of 209 000 shares at 12.80 SEK per share (originally 190 000 shares at 14.00 SEK per share). Since a previous board member in March this year exercised all his options, remaining options enabled subscription of 225 388 shares.
The Board chairman Klas Cramborn and the Board director Jan Richardsson have now requested exercise of their entire option holdings. Hereby Cramborn subscribes for 10 766 shares in option program 2012 och 44 000 shares in option program 2013, totally 54 766 shares. Richardsson subscribes for 11 000 shares in option program 2013.
Through these subscriptions, the equity of PHI increases by 881 639 SEK. The exercise of the options implies a dilution of 0.6 % for current shareholders. After registration of the new shares at Bolagsverket (Swedish Companies Registration Office), the total number of shares in PHI will amount to 11 642 705 and the share capital to 2 328 541 SEK.
To finance his subscription, Cramborn has sold 40 000 shares during the period May 8-10, 2017. After the exercise of his options, Cramborn´s holding will be 64 776 shares, an increase by 14 766 shares.
Richardsson`s holding (private and via company) will amount to 41 802 shares, an increase by 11 000 shares, after the exercise of his options.
After the transactions, remaining options will enable subscription of 159 622 shares, implying a dilution of 1.6 % for current shareholders.
This information is information that Phase Holographic Imaging is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at May 11, 2017.
Phase Holographic Imaging (PHI) leads the ground-breaking development of time-lapse cytometry instrumentation and software. With the first instrument introduced in 2011, the company today offers a range of products for long-term quantitative analysis of living cell dynamics that circumvent the drawbacks of traditional methods requiring toxic stains. Headquartered in Lund, Sweden, PHI trades through a network of international distributors. Committed to promoting the science and practice of time-lapse cytometry, PHI is actively expanding its customer base and scientific collaborations in cancer research, inflammatory and autoimmune diseases, stem cell biology, gene therapy, regenerative medicine and toxicological studies.